Whitepaper: Phenotypic drug discovery with high content screening

Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.

Turn subtle phenotypic responses into robust discoveries

Today’s drug discovery strategies require candidate compounds to fail early and cheaply in the discovery stage, rather than late and expensively in the clinical phase. Testing compounds from the beginning in physiologically relevant model systems and leveraging rich information from image-based screens are ways to focus on those compounds that give rise to the right phenotypic changes without undesirable effects on the system.

High Content Screening with detailed multiparametric assays in conjunction with powerful data visualisation and machine-learning tools provide a promising way to achieve this goal and turn phenotypic data into robust discoveries.

In this white paper, learn about:

• Why you should consider phenotypic vs. target based drug discovery strategies
• Challenges you should be aware of for phenotypic assays

How to maximise the return on your phenotypic assays